Otsuka Pharmaceuticals and Click Therapeutics announced that Rejoyn, a smartphone-based prescription digital therapeutic for major depressive disorder (MDD), scored FDA clearance to be used as an adjunct to clinician-managed care.
Rejoyn is a six-week remote treatment program to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional training...
During Monday's ViVE event in Nashville, panelists discussed how to collect unbiased data through partnerships and by gaining trust and increasing accessibility within communities.
"Data is generated, input by individuals — by humans — and as humans, we all have implicit biases. The first part is to recognize, acknowledge what those are, learn what those may be for you so then you can help...
New Jersey-based Otsuka Pharmaceutical Development & Commercialization has signed a three-year collaboration with Holmusk, a data science and digital health firm based in Singapore and New York. The deal is worth up to $4 million annually.
WHAT THEY DO
OPDC is an indirect unit of Otsuka Pharmaceutical Company, which is a subsidiary of Japan-based Otsuka Holdings. It develops and manufactures...
Over the last year, digital has transformed the caregiver experience, but pharma has also been undergoing a metamorphosis in order to reach patients.
During the pandemic, life science companies were pushed to reconfigure their care in order to meet the needs of some of the most at-risk patients. MobiHealthNews sat down with the leader of pharma giant Otsuka's Global Clinical Development on...
All around the world the coronavirus pandemic has led to an uptick in digital healthcare delivery models. While telemedicine is often touted as the poster child of digital success in 2020, digital therapeutics (DTx) also emerged as a player on the global stage.
"What we are seeing is digital therapeutics, while they won’t directly treat COVID, they are really an integral component of this...
Otsuka Pharmaceutical and Click Therapeutics have announced the launch of a new, fully remote clinical trial being conducted on Verily's Project Baseline platform.
Called the Mirai study, it will be measuring a digital therapeutics intervention's effectiveness in reducing symptoms of depression among adults who have a major depressive disorder (MDD) diagnosis and are on antidepressant monotherapy...
Picking through the scraps. Following the bankruptcy of 'digital pill' maker Proteus Digital Health, business partner and stakeholder Otsuka Pharmaceutical has been approved to purchase the digital health company's assets by a federal bankruptcy court judge, STAT reports.
Otsuka's bid was challenged by Novartis, two former Proteus executives and other investors, who argued that the agreed upon $...
Proteus Digital Health, maker of an ingestible sensor for tracking medication adherence, filed for Chapter 11 bankruptcy protection yesterday.
The news comes months after word that the company had furloughed much of its staff, reassessed its high-profile partnership with Otsuka Pharmaceutical and shifted away from its primary focus area of mental disorder treatment.
The "smart pill" maker...
It has been a tumultuous week in the realm of digital health partnerships. It started with word of Proteus Digital Health’s floundering business and failed investment round, which reports say was partially driven by cooling relations between the digital pill maker and its longtime patron Otsuka Pharmaceuticals. A few days later, Sanofi announced a company-wide strategy shift that found Onduo, its...
Proteus Digital Health, maker of an ingestible sensor system for treatment adherence monitoring, was forced to furlough many of its employees last month after a $100 million funding round didn’t close as expected, according to a weekend report from CNBC.
These employees were brought back after about two weeks after Proteus was able to secure $5 million in emergency funding, according to the...
